Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer

被引：0

作者：

Mattos, Bruna RaphaeliSilva ^{[1
]}

Cesca, Marcelle Goldner ^{[1
]}

Leite, Luciana de Moura ^{[1
]}

Tavares, Monique Celeste ^{[1
]}

Silva, Sinara Figueiredo ^{[1
]}

Pirolli, Rafaela ^{[1
]}

Fogassa, Camilla AlbinaZanco ^{[1
]}

Silva, Erick Figueiredo ^{[1
]}

Rocha, Francisca Giselle ^{[1
]}

Loose, Simone Klug ^{[1
]}

Campos, Fernando AugustoBatista ^{[1
]}

Sanches, Solange Moraes ^{[1
]}

de Lima, Vladmir ClaudioCordeiro ^{[1
]}

Ponde, Noam Falbel ^{[1
]}

机构：

[1] AC Camargo Canc Ctr, Sao Paulo, Brazil

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS4-40

引用

页数：2

共 50 条

[21] Correlation between HER2 amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2 positive breast cancer.
Antolin, Silvia
Garcia-Caballero, Lucia
Reboredo, Cristina
Molina Diaz, Aurea
Mosquera, Joaquin
Vazquez-Boquete, Angel
Gallego, Rosalia
Paz Santiago, Maria
Concha, Angel
Eva Perez, Maria
Calvo, Lourdes
Garcia-Caballero, Tomas
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[22] Predictors of Response to Standard Neoadjuvant Chemotherapy in Estrogen Receptor Positive, HER2 Negative Breast Cancer
Bhargava, R.
LABORATORY INVESTIGATION, 2012, 92 : 26A - 26A
[23] HER2 Expression in Triple-Negative Breast Cancer: Clinicopathologic Features and Response to Neoadjuvant Chemotherapy
Morante, Zaida
Otoya, Iris
Valdivieso, Natalia
Calle, Cindy
Fuentes, Hugo
Neciosup, Silvia
Castaneda, Carlos
Vidaurre, Tatiana
Falla, Martin
Colomo, Valeria
Gomez, Henry
CANCER RESEARCH, 2024, 84 (09)
[24] Predictors of Response to Standard Neoadjuvant Chemotherapy in Estrogen Receptor Positive, HER2 Negative Breast Cancer
Bhargava, R.
MODERN PATHOLOGY, 2012, 25 : 26A - 26A
[25] Evaluating the efficacy of neoadjuvant endocrine therapy in HER2 low vs. HER2 negative breast cancer: An NCBD analysis
Chong, Esther G.
Guo, Mengni
Castillo, Dani Ran
Bazan, Jose G.
Yap, Kelly Khai Li
Schultz-Costello, Katharine
Wu, S. Peter
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[26] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
Zhao, Jing
Zhang, Chao
Suo, Aili
Shi, Qiuying
Wei, Zhimin
Li, Zaibo
Krishnamurti, Uma
Li, Xiaoxian
MODERN PATHOLOGY, 2019, 32
[27] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
Zhao, Jing
Meisel, Jane
Suo, Aili
Zhang, Chao
Wei, Zhimin
Aneja, Ritu
Li, Zaibo
Nahta, Rita
Li, Xiaoxian
MODERN PATHOLOGY, 2019, 32
[28] Discordance in hormone receptor and HER2 status in breast cancer during neoadjuvant chemotherapy
Maeda, S.
Tohyama, H.
Tokai, H.
Kamohara, Y.
Nagata, Y.
Fujioka, H.
Itoh, M.
BREAST, 2011, 20 : S73 - S73
[29] Changes in Hormone Receptor and Her2 Status After Neoadjuvant Chemotherapy in Breast Cancer
Kaya, Ali Osman
Buyukberber, Suleyman
Yamac, Deniz
Coskun, Ugur
Yildiz, Ramazan
Yaman, Emel
Ozturk, Banu
Benekli, Mustafa
TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, 2010, 30 (02): : 469 - 473
[30] Evaluating Low HER2 Status in Breast Cancer Cases with Absent and Low HER2 Protein Expression
Ardor, Gokce
Komforti, Miglena
Hanna, Helena
Nassar, Aziza
LABORATORY INVESTIGATION, 2023, 103 (03) : S94 - S95

← 1 2 3 4 5 →